Article
Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease.
Arteriosclerosis, thrombosis, and vascular biology - 1 Sept 2010
Ibrahim Salam, Tetruashvily Mazell, Frey Alex J, Wilson Stephen J, Stitham Jeremiah, Hwa John, Smyth Emer M
Abstract excerpt
OBJECTIVE: Prostacyclin and thromboxane mediate opposing cardiovascular effects through their receptors, the prostacyclin receptor (IP) and thromboxane receptor (TP). Individuals heterozygous for an IP variant, IP(R212C), displayed exaggerated loss of platelet IP responsiveness and accelerated cardiovascular disease. We examined association of IP(R212C) into homo- and heterodimeric receptor complexes and the...
Topics
- Cardiovascular Diseases
- Cell Line
- Cyclic AMP
- Dimerization
- Dose-Response Relationship, Drug
- Endoplasmic Reticulum
- Epoprostenol
- Fluorescence Resonance Energy Transfer
- Genotype
- Heterozygote
